Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report

被引：9

作者：

Aslan, Jeylan ^{[1
]}

Shipstone, Michael A. ^{[1
]}

Sullivan, Louise M. ^{[2
]}

机构：

[1] Dermatol Anim, 263 Appleby Rd, Stafford Heights, Qld 4053, Australia

[2] QML Pathol, 11 Riverview Pl, Murrarie, Qld 4172, Australia

来源：

VETERINARY DERMATOLOGY | 2021年 / 32卷 / 04期

关键词：

JANUS KINASE INHIBITOR; DOGS;

D O I：

10.1111/vde.12976

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Canine cutaneous epitheliotropic T-cell lymphoma (CETL) is associated with a poor prognosis and without consistently beneficial treatment options. This case report describes a 9-year-old Staffordshire bull terrier with CETL treated with oclacitinib (0.7 mg/kg twice daily), resulting in partial remission that was maintained for three months. Further studies are warranted.

引用

页码：398 / +

页数：5

共 11 条

[1] Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production [J].

Banovic, Frane ;

Tarigo, Jaime ;

Gordon, Hannah ;

Barber, James P. ;

Gogal, Robert M., Jr. .

VETERINARY DERMATOLOGY, 2019, 30 (01) :17-+

[2] Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003-2015) [J].

Chan, Catherine M. ;

Frimberger, Angela E. ;

Moore, Antony S. .

VETERINARY DERMATOLOGY, 2018, 29 (02) :154-+

[3] The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog [J].

Collard, W. T. ;

Hummel, B. D. ;

Fielder, A. F. ;

King, V. L. ;

Boucher, J. F. ;

Mullins, M. A. ;

Malpas, P. B. ;

Stegemann, M. R. .

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2014, 37 (03) :279-285

[4] Canine cutaneous epitheliotropic T-cell lymphoma: a review [J].

Fontaine, J. ;

Bovens, C. ;

Bettenay, S. ;

Mueller, R. S. .

VETERINARY AND COMPARATIVE ONCOLOGY, 2009, 7 (01) :1-14

[5] Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy [J].

Gonzales, A. J. ;

Bowman, J. W. ;

Fici, G. J. ;

Zhang, M. ;

Mann, D. W. ;

Mitton-Fry, M. .

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2014, 37 (04) :317-324

[6] Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro [J].

Jasiecka-Mikolajczyk, Agnieszka ;

Jaroszewski, Jerzy J. ;

Maslanka, Tomasz .

RESEARCH IN VETERINARY SCIENCE, 2018, 121 :124-129

[7] Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic [J].

Laprais, Aurore ;

Olivry, Thierry .

BMC VETERINARY RESEARCH, 2017, 13

[8] Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer [J].

Mishra, Anjali ;

Sullivan, Laura ;

Caligiuri, Michael A. .

CLINICAL CANCER RESEARCH, 2014, 20 (08) :2044-2050

[9] Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas [J].

Moskowitz, Alison J. ;

Jacobsen, Eric ;

Ruan, Jia ;

Schatz, Jonathan H. ;

Obadi, Obadi ;

Motylinski, Kristin ;

Jarjies, Christine ;

Galasso, Natasha ;

Hancock, Helen ;

Davey, Theresa ;

Myskowski, Patricia ;

Dogan, Ahmet ;

Inghirami, Giorgio ;

Weinstock, David M. ;

Horwitz, Steven M. .

BLOOD, 2018, 132

[10] Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders [J].

Shouse, Geoffrey ;

Nikolaenko, Liana .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (06) :570-576

← 1 2 →